Upcoming webinar

The latest Panorama™: Lower no-call rate, exceptional low fetal fraction performance

Duration: 30-minute presentation with live Q&A

Available sessions:

Session 1: Thursday, June 18, 2026 | 9 AM PT | 12 PM ET

Session 2: Tuesday, June 23, 2026 | 3 PM PT | 6 PM ET

Registrants will receive a recording of the webinar approximately one week after the event.

Webinar overview:

The latest version of Panorama™ has reduced the no-call rate to just 0.5%, enabled by novel SNP-informed deep sequencing technology. Panorama™ now provides confident results for more patients, including those with low fetal fraction.

Panorama™ is the first and only NIPT with clinical validation data in a low fetal fraction cohort. Patients with low fetal fractions are associated with an increased risk of aneuploidy, and published literature suggests there may be challenges with sensitivity at low fetal fractions with counting-based methods.^1–3

The latest Panorama™ is validated by a prospective, blinded study with 3,323 samples with confirmatory diagnostic genetic testing. Results from this study demonstrated highly accurate clinical performance in patients with low fetal fractions.⁴

In this webinar, attendees will:

Learn about challenges with low fetal fraction and limitations of existing approaches to address them
See the data supporting the latest version of Panorama™, including the clinical validation for performance in common aneuploidies in a low fetal fraction cohort
Get an overview of Panorama™ reporting updates, including changes to atypical results reporting aimed to better support patient counseling for these types of results

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Available Webinar Sessions*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:

Sheetal Parmar, MS, CGC

Senior Vice President

Women’s Health Medical Affairs

Natera

Jennifer Saucier, MS, CGC

Vice President

Women’s Health Product Management

Natera

References:

1. Wright et al. Ultrasound Obstet Gynecol. 2015 Jan;45(1):48-54.

2. Canick et al. Prenat Diagn. 2013 Jul;33(7):667-74.

3. Palmoaki et al. Genet Med. 2011 Nov;13(11):913-920.

4. Internal data on file.

Panorama™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy